Lefty-1 Activators
Lefty-1 activators encompass a diverse array of chemical compounds that indirectly augment its functional activity, primarily by influencing signaling pathways that intersect with Lefty-1's role in Nodal signaling inhibition. Compounds like Retinoic Acid play a critical role in this process by modulating gene expression within the TGF-β pathway, where Lefty-1 operates. This modulation results in an enhanced ability of Lefty-1 to inhibit Nodal signaling. Similarly, inhibitors of BMP signaling, such as Dorsomorphin and LDN-193189, along with TGF-β receptor kinase inhibitors like SB431542 and LY364947, indirectly augment Lefty-1's activity. These compounds achieve their effects by reducing the activity of signaling pathways that either compete with or interact with Lefty-1, thus making its inhibition of Nodal signaling more effective. In addition, A-83-01, an inhibitor of the TGF-β type I receptor ALK5, and PD173074, an FGFR inhibitor, further contribute to this enhancement by modulating pathways that can affect Nodal signaling.
Moreover, compounds that influence Wnt signaling, such as CHIR99021, a GSK-3β inhibitor, IWP-2, an inhibitor of Wnt production, and BIO, a GSK-3 inhibitor, indirectly promote Lefty-1's activity. These compounds alter the dynamics of Wnt signaling, which can indirectly impact Nodal signaling pathways, thereby facilitating Lefty-1's inhibitory role. The inhibition of specific signaling components like ALK4/5/7 by SB505124 and Smad3 by SIS3 also supports Lefty-1's activity. By modulating the TGF-β signaling pathway, these inhibitors create a more favorable environment for Lefty-1 to effectively inhibit Nodal signaling. Collectively, these Lefty-1 activators, through their targeted modulation of cellular signaling pathways, particularly those intersecting with Nodal signaling, enhance Lefty-1's primary function as an inhibitor of Nodal signaling, demonstrating the complex interplay of cellular signaling in regulating protein function.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $65.00 $319.00 $575.00 $998.00 | 28 | |
Retinoic Acid enhances Lefty-1 activity by influencing cellular differentiation pathways. It modulates the expression of genes in the TGF-β pathway, which Lefty-1 is a part of, leading to an indirect enhancement of Lefty-1's inhibitory role on Nodal signaling. | ||||||
Dorsomorphin dihydrochloride | 1219168-18-9 | sc-361173 sc-361173A | 10 mg 50 mg | $182.00 $736.00 | 28 | |
Dorsomorphin indirectly enhances Lefty-1 activity by inhibiting BMP signaling. This inhibition allows Lefty-1 to more effectively exert its antagonistic effects on Nodal signaling, as BMP and Nodal pathways are interconnected. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB431542, a TGF-β receptor kinase inhibitor, indirectly enhances Lefty-1 activity by reducing competitive TGF-β signaling, thereby allowing Lefty-1 to be more effective in its inhibition of Nodal signaling. | ||||||
LY 364947 | 396129-53-6 | sc-203122 sc-203122A | 5 mg 10 mg | $105.00 $153.00 | 4 | |
LY364947, another TGF-β receptor kinase inhibitor, functions similarly to SB431542, indirectly enhancing Lefty-1 activity by inhibiting TGF-β signaling and thus allowing Lefty-1 to more effectively inhibit Nodal signaling. | ||||||
A 83-01 | 909910-43-6 | sc-203791 sc-203791A | 10 mg 50 mg | $198.00 $650.00 | 16 | |
A-83-01 inhibits TGF-β type I receptor ALK5, which indirectly enhances Lefty-1's activity by reducing signaling that competes with Lefty-1's inhibitory role in Nodal signaling. | ||||||
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $46.00 $140.00 $680.00 | 16 | |
PD173074 inhibits FGFR, which indirectly enhances Lefty-1 activity. This is because FGFR signaling can modulate Nodal signaling, and inhibition of FGFR allows Lefty-1 to more effectively inhibit Nodal signaling. | ||||||
4-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline | 1062368-24-4 | sc-476297 | 5 mg | $240.00 | ||
LDN-193189 inhibits BMP type I receptors ALK2/3/6, which indirectly enhances Lefty-1 activity. By inhibiting BMP signaling, it allows Lefty-1 to exert its inhibitory effects on Nodal signaling more effectively. | ||||||
GSK-3 Inhibitor XVI | 252917-06-9 | sc-221691 sc-221691A | 5 mg 25 mg | $153.00 $520.00 | 4 | |
CHIR99021 is a GSK-3β inhibitor that indirectly enhances Lefty-1 activity by modulating Wnt signaling. Alterations in Wnt signaling can affect Nodal signaling, thus indirectly enhancing Lefty-1's inhibitory role. | ||||||
IWP-2 | 686770-61-6 | sc-252928 sc-252928A | 5 mg 25 mg | $94.00 $286.00 | 27 | |
IWP-2 inhibits Wnt production, which can indirectly enhance Lefty-1 activity. By reducing Wnt signaling, IWP-2 can influence Nodal signaling pathways, where Lefty-1 acts as an inhibitor. | ||||||
GSK-3 Inhibitor IX | 667463-62-9 | sc-202634 sc-202634A sc-202634B | 1 mg 10 mg 50 mg | $57.00 $184.00 $867.00 | 10 | |
BIO is a GSK-3 inhibitor, which indirectly enhances Lefty-1 activity by modulating Wnt/β-catenin signaling. This modulation can affect Nodal signaling, indirectly enhancing Lefty-1's functional role. | ||||||